The Power Of A Platform Process For Lentiviral Vectors

By Kim Allen, Joanna Manoranjan, and Kerry Adamik, Miltenyi Bioindustry

The LVV platform process leverages transient transfection, rather than a stable packaging cell with set viral genes, enabling the ability to change the genes expressed and even change the envelope. Moreover, analytics are pre-qualified and included, cGMP documents are already written, and highly specialized staff already has been trained.

Potential partners and platforms can be differentiated in terms of their experience as well as critical metrics like batch failure/success rates, deviation rates, and titer/yield from preclinical through commercial production. The most viable LVV platform options offer a combination of predictability, flexibility, and reliability.

Choosing a full-scale CDMO for LVV at the start of a program can ultimately save a sponsor valuable resources by generating a better-performing vector and eliminating the need to change partners as you scale. Miltenyi Bioindustry’s streamlined preclinical-to-commercial-GMP work structure eliminates add-on fees, with a batch price that incorporates all project elements: the platform, helper plasmids, staff training, project manager, cell culture, and more.